Puma Biotechnology (PBYI) news
Recent news
Puma Biotechnology Q2 adjusted EPS USD 0.19 (corrects amount)
Puma Biotechnology (NASDAQ: PBYI) reported adjusted earnings per share (EPS) of $0.19 for the second quarter of 2026, according to its financial outlook and guidance provided in early 2026. This figure reflects the company’s non-GAAP adjusted net income for the period, which excludes stock-based…
AInvest Wire · Aug 6, 2026Puma Biotechnology - raises FY2026 net product revenue guidance to $205-209 mln
AInvest Wire · Aug 6, 2026CCI: CCI oks purchase of some stake in Puma SE by Ancat Holding GmbH
The Competition Commission of India (CCI) has approved the acquisition of a stake in PUMA SE by Ancat Holding GmbH, a subsidiary of Anta Sports Products Limited. The transaction involves the purchase of a 29.06% stake in PUMA from Artémis, the holding company of the Pinault family, for 1.5 billion…
AInvest Wire · Jun 9, 2026Puma Biotechnology reports inducement awards under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jun 3, 2026Puma SE shares down 3.2%
Puma SE (PUM.DE) shares fell 3.2% on June 1, 2026, trading at 28.70 euros per share, following a mixed earnings report and ongoing challenges in the global market. The company recently reported a quarterly revenue of €1.9 billion, which exceeded expectations by 2.7%, but also revealed statutory…
AInvest Wire · Jun 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.